The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the industry. A shift away from Schedule I status, often considered as outdated and hindering advancement, could unlock significant avenues for companies. Reduced regulatory restrictions, alongside greater access to banking and inve